Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Hemogenyx Pharmaceuticals Plc HOPHF OTC

Other OTC • Healthcare • Biotechnology • GB • USD

SharesGrow Score
11/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Hemogenyx Pharmaceuticals Plc (HOPHF) is a Biotechnology company in the Healthcare sector, currently trading at $2.33. It has a SharesGrow Score of 10/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $6M (loss), growing at -27919.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $3M against $897,514 equity (Debt-to-Equity (D/E) ratio 2.92, leveraged). Current ratio is 0.72 (tight liquidity). Debt-to-assets is 62.3%. Total assets: $4M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 0/100 (Fail), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

HOPHF SharesGrow Score Overview

22/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 0/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HOPHF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
HOPHF: +0%/yr revenue is, -27919.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
—
HEALTH N/A
N/A
No analyst coverage available for this stock.
✗
MOAT Fail
28/100
HOPHF: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.04-2.33
Volume25K
Avg Volume (30D)12.57K
Market Cap$14.97M
Beta (1Y)1.54
Share Statistics
EPS (TTM)-2.13
Shares Outstanding$3.3M
IPO Date2021-01-12
Employees16
CEOVladislav Sandler
Financial Highlights & Ratios
Gross Profit$-799.81K
EBITDA$-5.15M
Net Income$-5.62M
Operating Income$-7.16M
Total Cash$159.27K
Total Debt$2.62M
Net Debt$2.46M
Total Assets$4.21M
Price / Earnings (P/E)-1.1
Analyst Forecast
Company Info
CountryGB
ExchangeOther OTC
CurrencyUSD
ISINGB00BQVXM815

Price Chart

Track all markets on TradingView
HOPHF
Hemogenyx Pharmaceuticals Plc ↗  ·  Other OTC
Healthcare • Biotechnology
0.04 52WK RANGE 2.33

People Also View

CELC
CELC
Celcuity Inc.
$123.47
+2.17%
 ELVN
ELVN
Enliven Therapeutics, Inc.
$43.95
-2.01%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.60
+0.49%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$18.23
+4.17%
 MNPR
MNPR
Monopar Therapeutics Inc.
$57.91
-0.02%
 STTK
STTK
Shattuck Labs, Inc.
$7.17
+5.75%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 PRLD
PRLD
Prelude Therapeutics Incorporated
$5.52
+25.45%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message